
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Roman DBDR Acquisition Corp. II Ordinary shares (DRDB)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: DRDB (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 1.88% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 9.87 - 10.43 | Updated Date 05/1/2025 |
52 Weeks Range 9.87 - 10.43 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Roman DBDR Acquisition Corp. II Ordinary shares
Company Overview
History and Background
Roman DBDR Acquisition Corp. II was a blank check company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. They did not have specific milestones as a separate company, but they merged with Comera Life Sciences (Nasdaq: CMRA) in May 2023.
Core Business Areas
- SPAC: A special purpose acquisition company (SPAC) that sought to acquire another company.
Leadership and Structure
The leadership team consisted of seasoned investment professionals. As a SPAC, it had a board of directors and management team responsible for identifying and executing a merger. After merging with Comera Life Sciences, the new company has its own leadership team.
Top Products and Market Share
Key Offerings
- SPAC IPO: Roman DBDR Acquisition Corp. II's main offering was its initial public offering (IPO) to raise capital to find and merge with a target company. Market share data is not applicable for SPACs. Competitors would be other SPACs.
Market Dynamics
Industry Overview
The SPAC market experienced a boom and subsequent correction. Many SPACs struggled to find suitable merger targets or complete deals. The market is currently much more selective.
Positioning
Roman DBDR Acquisition Corp. II aimed to be a successful SPAC. However, after the merger with Comera, they are now considered one and the same.
Total Addressable Market (TAM)
TAM depends on the industry of the company they acquired. As a SPAC, this metric is not applicable until the acquisition.
Upturn SWOT Analysis
Strengths
- Experienced Management Team (Pre-Merger)
- Capital Raised Through IPO (Pre-Merger)
Weaknesses
- Dependence on Finding a Suitable Merger Target (Pre-Merger)
- Dilution of Shareholder Value (Common for SPACs)
Opportunities
- Successful Merger with a High-Growth Company
- Capitalize on Market Trends
Threats
- Failure to Find a Suitable Merger Target (Pre-Merger)
- Market Volatility
- Increased Regulatory Scrutiny of SPACs
Competitors and Market Share
Key Competitors
- No direct competitors as it was a SPAC pre-merger
Competitive Landscape
As a SPAC, competition was with other SPACs to find attractive merger targets.
Growth Trajectory and Initiatives
Historical Growth: No historical growth as a standalone entity prior to merger.
Future Projections: Growth depends on the company that was acquired and their future projects.
Recent Initiatives: The merger with Comera Life Sciences.
Summary
Roman DBDR Acquisition Corp. II was a SPAC that completed a merger with Comera Life Sciences. As such, it no longer exists as a separate entity. Its success is now tied to the performance of Comera. The success of RDIB depended on finding a suitable target and efficiently deploying its capital.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Financial News Sources
Disclaimers:
Data is based on publicly available information and may not be complete. SPACs are inherently risky investments.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Roman DBDR Acquisition Corp. II Ordinary shares
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2025-02-03 | CEO & Chairman of the Board Mr. Dixon R. Doll Jr. | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://www.romandbdr.com |
Full time employees - | Website https://www.romandbdr.com |
Roman DBDR Acquisition Corp. II does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the cybersecurity, artificial intelligence, or financial technology industries. The company was incorporated in 2024 and is based in Boca Raton, Florida.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.